MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00277-023-05443-8

Медицинская библиотека · Annals of hematology · 2023

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.

Barilà Gregorio, Quaglia Francesca Maria, Furlan Anna, Pescosta Norbert, Bonalumi Angela, Marcon Chiara, Pascarella Anna, Tinelli Martina, De March Elena, Lico Albana, Sartori Roberto, Clissa Cristina, De Sabbata Giovanni, Nappi Davide, Porrazzo Marika, De Marchi Roberta, Pavan Laura, Tosetto Alberto, Gherlinzoni Filippo, Krampera Mauro, Bassan Renato, Patriarca Francesca, Semenzato Gianpietro, Zambello Renato

СтатьяПеревод пока не подготовлен

Аннотация

Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though only a small fraction of Len-R patients was included in the pivotal trial. This real-life study aimed to evaluate the efficacy and safety of the D-VD regimen in a cohort that exclusively enrolled Len exposed or refractory MM patients. The study cohort included 57 patients affected by relapsed/refractory MM. All patients were previously exposed to Len, with 77.2% being refractory. The overall response rate (ORR) was 79.6% with 43% of cases obtaining at least a very good partial response (VGPR). The D-VD regimen showed a favorable safety profile, with low frequency of grade 3-4 adverse events, except for thrombocytopenia observed in 21.4% of patients. With a median follow-up of 13 months, median progression-free survival (PFS) was 17 months. No significant PFS differences were observed according to age, ISS, LDH levels, type of relapse, and high-risk FISH. Len exposed patients displayed a PFS advantage as compared to Len refractory patients (29 vs 16 months, p = 0.2876). Similarly, patients treated after Len maintenance showed a better outcome as compared to patients who had received a full-dose Len treatment (23 vs 13 months, p = 0.1728). In conclusion, our real-world data on D-VD combination showed remarkable efficacy in Len-R patients, placing this regimen as one of the standards of care to be properly taken into account in this MM setting.

Для цитирования: Barilà Gregorio, Quaglia Francesca Maria, Furlan Anna, Pescosta Norbert, Bonalumi Angela, Marcon Chiara, Pascarella Anna, Tinelli Martina, De March Elena, Lico Albana, Sartori Roberto, Clissa Cristina, De Sabbata Giovanni, Nappi Davide, Porrazzo Marika, De Marchi Roberta, Pavan Laura, Tosetto Alberto, Gherlinzoni Filippo, Krampera Mauro, Bassan Renato, Patriarca Francesca, Semenzato Gianpietro, Zambello Renato. A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.. Annals of hematology. 2023. DOI: 10.1007/s00277-023-05443-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.